As the delta variant sweeps the world, researchers are tracking how well vaccines protect against it — and getting different answers.
In the U.K., researchers reported in May that two doses of the Pfizer-BioNTech vaccine had an effectiveness of 88% protecting against symptomatic disease from delta. A June study from Scotland concluded the vaccine was 79% effective against the variant, and on Saturday a team of researchers in Canada pegged its effectiveness at 87%.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.